REVB - Revelation Biosciences, Inc.
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $4.3M
- Beta
- -0.14
- 52-Week Range
- 0.875-13.8
- CEO
- James Rolke
- Employees
- 8
- IPO Date
- Nov 17, 2020
- Exchange
- NASDAQ
REVB Options Snapshot
Options pricing data for REVB is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.
What This Page Covers
The REVB overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked REVB overview questions
- What is REVB?
- REVB is the ticker symbol for Revelation Biosciences, Inc., a listed security. Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. Listed on NASDAQ. REVB is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What are REVB's key statistics?
- Revelation Biosciences, Inc. (REVB) carries a market capitalization of $4.3M, beta of -0.14 relative to the broader market, 52-week range of 0.875-13.8. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does REVB belong to?
- Revelation Biosciences, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare REVB's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the REVB data on this page?
- Options snapshots refresh after each trading session; if no snapshot is currently posted for REVB, it usually reflects low options liquidity or a recently listed name. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).